Navigation Links
Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids

t, no statistically significant changes in endometrial thickness were detected among the women who underwent ultrasound measurements of endometrial thickness at various time points. This study uses an endometrial thickness cut-off of 14mm after three months of dosing to determine whether or not a woman is allowed to proceed into an ongoing open label study. For those patients that were evaluated 9 patients at the 12.5 mg dose and 4 patients at the 25 mg dose exhibited an endometrium greater than 14 mm compared to 6 patients on placebo. An expert panel of pathologists will review all of the biopsies using the WHO criteria in addition to a specific classification created for the analysis of the histology in this study. Fifty-eight patients have rolled into a one-year open label extension study.

All reproductive hormones remained in the normal range and there is no indication of bone loss using evaluating markers of bone resorption. In fact, there was a statistically significant increase in osteocalcin in the two Proellex groups. Osteocalcin is a marker associated with bone formation. In addition there was no change in urinary 24 hour cortisol excretion or serum adrenocorticotropic hormone (ACTH) indicating a lack of antiglucocorticoid activity at the receptor level.

Both doses of Proellex were well tolerated. The number of adverse events judged to be treatment related by the investigators in the Proellex 12.5 and 25 mg treatment groups were similar in incidence to placebo. The exception was the occurrence of amenorrhea (an expected drug effect) in 78.6% and hot flashes in 16.7% of all Proellex treated patients, respectively. The hot flashes were not dose dependent. The severity of the hot flashes was generally mild to moderate as were the vast majority of the other adverse events. On average, there were no clinically significant changes in other laboratory measurements of safety including liver enzymes.

"We are very pleased with these results," co
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:3/4/2015)... , March 4, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... will ring The Opening Bell ® of the ... 2015. Asterias began trading as an NYSE MKT listed ... York Stock Exchange is a trusted partner to Asterias ...
(Date:3/4/2015)... OAKS, Calif. , March 4, 2015 ... Board of Directors today declared a $0.79 per share ... will be paid on June 5, 2015, to all ... on May 14, 2015.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:3/4/2015)... 4, 2015  NxStage Medical, Inc. (Nasdaq: NXTM ... that Jeffrey H. Burbank , Chief Executive Officer, will ... Miami, FL on Wednesday, March 11 th ... the event will be made available at http://ir.nxstage.com ... NxStage NxStage Medical, Inc. (Nasdaq: NXTM ...
Breaking Medicine Technology:Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3Amgen Announces 2015 Second Quarter Dividend 2Amgen Announces 2015 Second Quarter Dividend 3NxStage to Present at the Barclays Capital Global Healthcare Conference 2
... Based on its recent analysis of the personal emergency ... with the 2010 North American Frost & Sullivan Award ... BeClose System and its applications in the "aging independently" ... While PERS have provided a health monitoring service for ...
... Inc. (Nasdaq: OPTR ) today announced that the ... the Company,s New Drug Application (NDA) for fidaxomicin for the ... reducing the risk of recurrence when used for treatment of ... for six-month Priority Review, and has assigned a Prescription Drug ...
Cached Medicine Technology:Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 3Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 4Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 2Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 3Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 4
(Date:3/4/2015)... 2015 Ultraman Florida is a grueling ... 261.4 mile bike, and 52.4 mile run. Christian Isakson ... 24:45:45. , "This race was awesome and tough," Isakson ... and sponsors for supporting me through every part of ... a total of 40 select participants invited from across ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 FDA’s New ... , **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. ... investigators generally know within four hours of an inspection ... manufacturer is on their “good” list, they’ll merely ask ... a manufacturer is on the “bad” list, the manufacturer ...
(Date:3/4/2015)... Concord, NH (PRWEB) March 04, 2015 ... the natural frozen food category, will attend this year’s ... from its newest product line. With this new line, ... meals in the natural channel, continues its commitment to ... the fastest growing frozen brand in the natural channel, ...
(Date:3/4/2015)... 2015 The print component of “Organic ... Francisco Chronicle with a circulation of approximately 173,000 copies ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... is composed of heat-dried microbes that have digested the ...
(Date:3/4/2015)... 04, 2015 The New Mel Brooks ... music, will be performed by the award-winning Drama Department ... this March 6-22, 2015, on Fridays, Saturdays and Sundays. ... High School (27118 Silver Spur Road, Rolling Hills ... the program or may be purchased on-line at ...
Breaking Medicine News(10 mins):Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
... Children With Food,Allergies, FAIRFAX, Va., Feb. 11 ... announce the release of two animated,DVDs that both entertain ... Couldn,t Eat Peanuts ... Goes to School and,Alexander, the ... help,children cope with their own allergies and teach other ...
... Corporation,(NYSE: CSK ), a leading international manufacturer ... of printed pharmaceutical,leaflets in North America, today announced ... Long Island, N.Y., and relocating,from its current location ... business has grown substantially since we moved to ...
... from seven countries, including teams of robotics and brain ... been set up with the aim of imitating nature. ... in the animal kingdom, the multinational team is developing ... whiskered robot will be able to quickly locate, identify ...
... the American Academy ... of Dermatology, ... indicates the 8-oxo-guanine DNA glycosylase (OGG1),encapsulated in liposomes is an effective ... and increasing,collagen production in UV irradiated skin cells. The data was ...
... 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ:,NRMX; TSX: NRM) ... Dr.,Francesco Bellini, Neurochem,s Chairman, President and Chief Executive,Officer, ... the new,nutraceutical business, will present Neurochem,s strategy at ... held at the Waldorf-Astoria, in New York,(NY). The ...
... Complex fibroadenomas have a low incidence of malignancy, so ... and avoid surgical biopsy, according to a new study ... Medical Center in Jerusalem. , A fibroadenoma is a ... young women. They are not usually associated with breast ...
Cached Medicine News:Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 2Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 3Health News:Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 3Health News:AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair 2Health News:AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair 3Health News:Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live 2Health News:Study finds patients with complex fibroadenomas can avoid surgery 2
Shandon Slide Mailers and Envelopes...
Shandon Stackable Slide Storage Cabinet...
Shandon Slide File Storage System...
Shandon Plastic Slide Boxes...
Medicine Products: